PTG 300

Drug Profile

PTG 300

Alternative Names: PTG-300

Latest Information Update: 12 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protagonist Therapeutics
  • Class Peptides
  • Mechanism of Action Iron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Beta-thalassaemia

Most Recent Events

  • 25 May 2017 Pharmacodynamics data from preclinical trials in Iron overload released by Protagonist Therapeutics
  • 21 May 2017 Phase-I clinical trials in Beta-thalassaemia (In volunteers) in Australia (SC) (ACTRN12617000453381)
  • 05 May 2017 Preclinical trials in Iron overload in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top